Changes of Plasma Adiponectin Levels after Smoking Cessation
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Objective Cigarette smoking is associated with a variety of health problems including cardiovascular, pulmonary, neoplasms, endocrinopathies including diabetes, the metabolic syndrome, and chronic inflammation. Adiponectin is an adipocyte-derived plasma protein that is closely associated with insulin sensitivity and the metabolic syndrome. The aim of this study was to evaluate the changes of plasma adiponectin levels after smoking cessation. Methods Thirty seven smokers that wanted to stop smoking without any nicotine replacement therapy or medication were recruited for this study. Fifteen smokers succeeded in stopping smoking (validated by urine cotinine levels ≤50 ng/mL) and 22 smokers failed. Therefore, only the 15 that succeeded were included in the analysis. The plasma adiponectin levels were determined using a commercially available enzyme-linked immunosorbent assay. Results The mean age of the successful 15 was 35±9.3 years old. They were all males. The daily smoking habit was a mean of 13.5±5.4 cigarettes per day. The mean Nicotine Dependence Syndrome Scale (NDSS) and Fagerstrom Test for Nicotine Dependence (FTND) scores were 55.6±9.6 and 2.9±1.9. During the study period of three months, the mean body mass index (BMI), body fat mass (BFM), waist-hip ratio (WHR) and body weight increased by 1.1 kg/m2, 3.0%, 0.02%, and 2.9 kg, respectively. The baseline mean adiponectin level in the subjects was 11.9±5.2 mg/L. The mean adiponectin levels measured at one and three months were 16.0±5.1 mg/L and 14.7±4.5 mg/L respectively. The mean plasma adiponectin levels of the successful group was significantly increased after four weeks when compared to the baseline (z=-2.401, p=0.016). However, the decrease in plasma adiponectin levels at one and three months was not statistically significant. Conclusion Even though the decrease over the next two months was not significant, these findings, the increase of plasma level of adiponectin after smoking cessation, provide preliminary data for future research on the possible mechanisms associated with smoking cessation and changes in body metabolism.
Abstract
Objective Cigarette smoking is associated with a variety of health problems including cardiovascular, pulmonary, neoplasms, endocrinopathies including diabetes, the metabolic syndrome, and chronic inflammation. Adiponectin is an adipocyte-derived plasma protein that is closely associated with insulin sensitivity and the metabolic syndrome. The aim of this study was to evaluate the changes of plasma adiponectin levels after smoking cessation. Methods Thirty seven smokers that wanted to stop smoking without any nicotine replacement therapy or medication were recruited for this study. Fifteen smokers succeeded in stopping smoking (validated by urine cotinine levels ≤50 ng/mL) and 22 smokers failed. Therefore, only the 15 that succeeded were included in the analysis. The plasma adiponectin levels were determined using a commercially available enzyme-linked immunosorbent assay. Results The mean age of the successful 15 was 35±9.3 years old. They were all males. The daily smoking habit was a mean of 13.5±5.4 cigarettes per day. The mean Nicotine Dependence Syndrome Scale (NDSS) and Fagerstrom Test for Nicotine Dependence (FTND) scores were 55.6±9.6 and 2.9±1.9. During the study period of three months, the mean body mass index (BMI), body fat mass (BFM), waist-hip ratio (WHR) and body weight increased by 1.1 kg/m2, 3.0%, 0.02%, and 2.9 kg, respectively. The baseline mean adiponectin level in the subjects was 11.9±5.2 mg/L. The mean adiponectin levels measured at one and three months were 16.0±5.1 mg/L and 14.7±4.5 mg/L respectively. The mean plasma adiponectin levels of the successful group was significantly increased after four weeks when compared to the baseline (z=-2.401, p=0.016). However, the decrease in plasma adiponectin levels at one and three months was not statistically significant. Conclusion Even though the decrease over the next two months was not significant, these findings, the increase of plasma level of adiponectin after smoking cessation, provide preliminary data for future research on the possible mechanisms associated with smoking cessation and changes in body metabolism.
참고문헌 (30)
- The Health Consequences of Smoking: A Report of the Surgeon General, "US Department of Health and Human Services", US Department of Health and Human Services, Public Health Service, Office of the Surgeon General, ~ (2004)
- Beltowski J, "Adiponectin and its role in cardiovascular diseases", Cardiovasc Hematol Disord Drug Targets, 8, pp.7~46 (2008)
- Matsuzawa Y, "Adiponectin and metabolic syndrome", Arterioscler Thromb Vasc Biol, 24, pp.29~33 (2004)
- Havel PJ, "Control of energy homeostasis and insulin action by adipocyte hormones: leptin, acylation stimulating protein, and adiponectin", Curr Opin Lipidol, 13, pp.51~59 (2002)
- Kumada M, "Association of hypoadiponectinemia with coronary artery disease in men", Arterioscler Thromb Vasc Biol, 23, pp.85~89 (2003)
- Pischon T, "Plasma adiponectin levels and risk of myocardial infarction in men", JAMA, 291, pp.1730~1737 (2004)
- Miyazaki T, "Adipocyte derived plasma protein, adiponectin, is associated with smoking status in patients with coronary artery disease", Heart, 89, pp.663~ (2003)
- Thamer C, "Reduced adiponectin serum levels in smokers", Atherosclerosis, 179, pp.421~422 (2005)
- Efstathiou SP, "Smoking cessation increases serum adiponectin levels in an apparently healthy Greek population", Atherosclerosis, 205, pp.632~636 (2009)
- Takefuji S, "Smoking status and adiponectin in healthy Japanese men and women", Prev Med, 45, pp.471~475 (2007)
- American Psychiatric Association, "Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition" (1994), American Psychiatric Association
- Heatherton TF, "The Fagerstrom test for nicotine dependence: a revision of the Fagerstrom tolerance questionnaire", Br J Addict, 86, pp.1119~1127 (1991)
- Iwashima Y, "Association of hypoadiponectinemia with smoking habit in men", Hypertension, 45, pp.1094~1100 (2005)
- Abbasi F, "The relationship between plasma adiponectin concentration and insulin resistance is altered in smokers", J Clin Endocrinol Metab, 91, pp.5002~5007 (2006)
- Patel JV, "Circulating serum adiponectin levels in patients with coronary artery disease: relationship to atherosclerotic burden and cardiac function", J Intern Med, 264, pp.593~598 (2008)
- Cnop M, "Relationship of adiponectin to body fat distribution, insulin sensitivity and plasma lipoproteins: evidence for independent roles of age and sex", Diabetologia, 46, pp.459~469 (2003)
- Staiger H, "Relationship of serum adiponectin and leptin concentrations with body fat distribution in humans", Obes Res, 11, pp.368~372 (2003)
- Canoy D, "Cigarette smoking and fat distribution in 21,828 British men and women: a population-based study", Obes Res, 13, pp.1466~1475 (2005)
- Bamia C, "Tobacco smoking in relation to body fat mass and distribution in a general population sample", Int J Obes Relat Metab Disord, 28, pp.1091~1096 (2004)
- Dallosso HM, "The role of smoking in the regulation of energy balance", Int J Obes, 8, pp.365~375 (1984)
- Ferrara CM, "Weight gain and adipose tissue metabolism after smoking cessation in women", Int J Obes Relat Metab Disord, 25, pp.1322~1326 (2001)
- Filozof C, "Smoking cessation and weight gain", Obes Rev, 5, pp.95~103 (2004)
- Moffatt RJ, "Cessation from cigarette smoking: changes in body weight, body composition, resting metabolism, and energy consumption", Metabolism, 40, pp.465~470 (1991)
- Stamford BA, "Effects of smoking cessation on weight gain, metabolic rate, caloric consumption, and blood lipids", Am J Clin Nutr, 43, pp.486~494 (1986)
- Harvey J, "Leptin regulation of neuronal excitability and cognitive function", Curr Opin Pharmacol, 7, pp.643~647 (2007)
- van der Lely AJ, "Biological, physiological, pathophysiological, and pharmacological aspects of ghrelin", Endocr Rev, 25, pp.426~457 (2004)
- Lee H, "Increased leptin and decreased ghrelin level after smoking cessation", NEUROSCIENCE LETTERS, 409, pp.47~51 (2006), ELSEVIER IRELAND LTD
- Spranger J, "Adiponectin does not cross the blood-brain barrier but modifies cytokine expression of brain endothelial cells", Diabetes, 55, pp.141~147 (2006)
- Qi Y, "Adiponectin acts in the brain to decrease body weight", Nat Med, 10, pp.524~529 (2004)
- Kubota N, "Adiponectin stimulates AMP-activated protein kinase in the hypothalamus and increases food intake", Cell Metab, 6, pp.55~68 (2007)